Total and nondialyzable hydroxyproline excretion in stage D2 prostate cancer

Stanley C. Hopkins, Genaro M. Palmieri, Harvey B. Niell, Mohammad Moinuddin, Mark S. Soloway

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Hydroxyproline is excreted in urine as a breakdown product of normal bone turnover: A dialyzable (D) fraction (90% of total) reflects active bone destruction and a nondialyazble (ND) fraction reflects bone growth/regrowth. In metastatic prostate cancer where blastic osseous metastases predominate, disease progression on bone scan correlated with elevation of both total hydroxyproline excretion (7.84 + 1.28, P < 0.001) and the ND urinary level (0.94 ± 0.20, P < 0.01). In patients with a serially stable/improving scan, urinary excretion of each fraction (2.18 + 0.27 and 0.27 ± 0.01) was similar to that of men with no evidence of disease. For Stage D2 prostate cancer, these two markers satisfactorily monitor osseous activity in the intervals between serial bone scintigraphy.

Original languageEnglish (US)
Pages (from-to)117-121
Number of pages5
JournalCancer
Volume53
Issue number1
DOIs
StatePublished - Jan 1 1984

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Total and nondialyzable hydroxyproline excretion in stage D<sub>2</sub> prostate cancer'. Together they form a unique fingerprint.

  • Cite this